TransCode Therapeutics Financials - Benzinga

TransCode Therapeutics Inc

RNAZNASDAQ

Trade with Public

Trade with Public

$1.61

-0.11-6.4%

Last update: Sep 16, 5:31 PM

Overview News Earnings Forecast Price TargetsFinancialsSentiment Ownership Compare Stock Report

TransCode Therapeutics Financials

TransCode Therapeutics (RNAZ) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
TransCode Therapeutics Q1 EPS $(21.28) Up From $(70.16) YoY

TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(21.28) per share. This is a 69.67 percent increase over losses of $(70.16) per share from the same period last year.

Benzinga Newsdesk

PRO
Reported May 14, 2025: TransCode Therapeutics Q1 EPS $(2.51) Misses $(2.00) Estimate

TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $(2.00) by 25.5 percent. This is a 88.24 percent increase over losses of $(21.35) per

Benzinga Newsdesk

Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday

Avi Kapoor

Nasdaq Dips 1.5%; Home Depot Issues Weak Forecast

Avi Kapoor

Gold Moves Higher; Coca-Cola Increases FY24 Forecast

Avi Kapoor

Crude Oil Down 2%; GE Aerospace Earnings Top Views

Avi Kapoor